Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer

NCT07680088 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Anal Squamous Cell Carcinoma

Interventions

DRUG: Lenvatinib
DRUG: Pembrolizumab

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]